MabVax Therapeutics Holdings Inc (MBVX.OQ)
25 Apr 2018
Get access to over 18 million research reports from over 1,700 sources.
For several years, Reuters.com has provided analyst research reports for downloading. In an effort to streamline our website, analyst research will now be available from our dedicated page for Thomson Reuters On Demand, and the Reuters service will discontinue as of September 30, 2016.
Thomson Reuters On Demand provides over 18 million research reports from 1,700 sources.
Moreover, Thomson Reuters On Demand offers fast and cost-effective solutions that would allow you to retrieve information on:
- private equity
- third-party document and information retrieval
- and much, much more…
Click here to request a report and the team of expert analysts will get back to you shortly, to ensure you get the report you need.
|65||2015||Chairman of the Board, President, Chief Executive Officer|
|70||2014||Chief Financial Officer|
|74||2014||Chief Science Officer, Director|
|61||2014||Vice President - Pharmaceutical Development and Operations|
|60||2016||Vice President and Chief Business Officer|
- BRIEF-MabVax Therapeutics Regains Compliance With NASDAQ's $1.00 Minimum Bid Price Maintenance Requirement
- BRIEF-Mabvax Therapeutics Reports Positive Safety Results From Initial Cohort Of MVT-1075
- BRIEF-MabVax Therapeutics Says Reverse Stock Split Is Scheduled To Be Effective With Opening Of Trading On Feb 16
- BRIEF-Barry Honig Reports 4.99 Pct Stake In MabVax Therapeutics
- BRIEF-John Stetson Reports 4.99 Pct Stake In Mabvax Therapeutics Holdings